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ABSTRACT
Newborn screening for cystic fibrosis offers the opportunity for early intervention
and improved outcomes. This summary, resulting from a workshop sponsored by
the Cystic Fibrosis Foundation to facilitate implementation of widespread high
quality cystic fibrosis newborn screening, outlines the steps necessary for success
based on the experience of existing programs. Planning should begin with a
workgroup composed of those who will be responsible for the success of the local
program, typically including the state newborn screening program director and
cystic fibrosis care center directors. The workgroup must develop a screening
algorithm based on program resources and goals including mechanisms available
for sample collection, regional demographics, the spectrum of cystic fibrosis disease
to be detected, and acceptable failure rates of the screen. The workgroup must also
ensure that all necessary guidelines and resources for screening, diagnosis, and
care be in place prior to cystic fibrosis newborn screening implementation. These
include educational materials for parents and primary care providers; systems for
screening and for providing diagnostic testing and counseling for screen-positive
infants and their families; and protocols for care of this unique population. This
summary explores the benefits and risks of various screening algorithms, including
complex situations that can occur involving unclear diagnostic results, and pro-
vides guidelines and sample materials for state newborn screening programs to
develop and implement high quality screening for cystic fibrosis.
www.pediatrics.org/cgi/doi/10.1542/
peds.2006-1993
doi:10.1542/peds.2006-1993
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CYSTIC FIBROSIS (CF) is one of the most commonlife-shortening genetic diseases in the United
States, affecting 30 000 children and young adults.
Because early treatment improves outcome1–15 and the
Centers for Disease Control and Prevention has stated
that the addition of CF to state newborn screening (NBS)
programs is justified,16 there has been increased interest
in adding CF to state NBS programs. Individuals who are
diagnosed with CF through NBS have improved nutri-
tional status,17 better growth,14 and fewer hospitaliza-
tions,17–19 whereas a delayed diagnosis can result in sig-
nificant cognitive dysfunction20 and nutritional failure.4
NBS has been shown to decrease the risk of life-threat-
ening complications21 or death21,22 from CF in infancy or
early childhood. Families of those with CF also benefit
substantially from CF NBS, because they avoid the av-
erage 15-month delay between onset of symptoms and
diagnosis17 along with the accompanying anxiety, frus-
tration, and emotional distress.23 Costs of diagnosis, and
possibly treatment (through fewer hospitalizations), are
reduced by NBS.24 Finally, families can benefit from
genetic counseling and identification of CF in older sib-
lings as a result of NBS discovery of CF mutations.
Although CF NBS offers tremendous benefits for in-
dividuals diagnosed with CF and their families, it is
accompanied by risks that also must be considered for
optimal NBS-program design. These risks include the
potential that infants with CF could have a delayed
diagnosis by primary care providers (PCPs) who believe
a negative NBS result is definitive,25 and that infants who
are properly identified with CF by the screen could be
exposed to health care–acquired infections during the
diagnostic evaluation or early treatment.23 The families
of infants with a positive screening result but not CF
could experience unnecessary anxiety before the diag-
nostic result,26,27 and doubts regarding the health of their
normal infant may persist even afterward.28–31 Recogni-
tion of these risks is vital for optimal NBS-program de-
sign.
Components of a well-designed system necessary to
address these issues successfully, as determined at a
workshop held by the CF Foundation and attended by
representatives from numerous state and international
NBS programs, government agencies, and CF Founda-
tion–accredited care centers (see “Acknowledgments”),
are described here. The CF Foundation recommends
implementation of CF screening in all newborns, with
appropriate attention to these guidelines to reduce risks
and maximize benefits for all participants
The goal of CF NBS programs should be to provide
infants with CF an early opportunity to receive special-
ized medical care that will assist them in maintaining
normal growth and development and delay pulmonary
infection, with its associated subsequent decline of lung
function. To that end, CF NBS programs should be inte-
grated within established systems such as state-based
NBS programs to assure comprehensive education, test-
ing, tracking, follow-up, and outcomes assessments.
These NBS programs provide opportunity for early iden-
tification and treatment of infants who have disorders
that otherwise would go unrecognized before irrevers-
ible clinical damage. This early opportunity is possible
because indicators of disorders are detectable in the dried
blood spot specimens that are collected universally from
the newborn population at 2 days of age during a
presymptomatic period. NBS as a successful population-
based public health service began in the early 1960s
when statewide screening for phenylketonuria was first
implemented.32 Since that time, it has become a service
offered by all states and most industrialized nations and
includes screening for a variety of disorders.
NBS programs support sophisticated systems for co-
ordination of their educational, laboratory, communica-
tions, and clinical services (ref 33 and Table 1). The
particular disorders that are screened by each state’s
program are determined by state authority (state lists are
available at http://genes-r-us.uthscsa.edu/nbsdisorders.
htm). NBS programs can and do add new disorders,
some of which are universally required and some of
which are optional. The determination of whether CF is
included in a state’s NBS panel and, if so, whether it is
included as a required (mandatory) or optional screen is
in the purview of the state authority.
This document provides a guide to some initial pro-
cesses involved in the implementation of CF NBS. The
best way to conduct CF NBS in a particular region will
depend on a number of complex issues. Systematic plan-
ning by the state and a CF NBS advisory body will
maximize opportunity for success.
SYSTEMATIC PLANNING FOR CF NBS
To plan properly for CF NBS implementation, it is help-
ful to assemble a workgroup composed of those who will
have operational responsibility for the local CF NBS
program. Typically, this would include the state NBS
program director and all of the center directors of the CF
clinical care programs in the state. Some states may
choose to have a larger working group that includes key
support personnel such as CF clinic nurses, genetic
counselors or directors of accredited sweat-testing facil-
ities, and parents of children with CF. Initially, the CF
NBS workgroup should focus discussions on the practical
implications of various algorithms for screening and its
follow-up to develop protocols and outline expected
lines of responsibility (Table 2). As with other collabo-
rations between multidisciplinary experts, it is likely that
the CF NBS workgroup will function most smoothly
when agreements about problematic issues (eg, costs,
staffing, and authorship on publications that might be
generated on the basis of data collected by the group) are
in place. Ideally, the CF NBS workgroup would be an
information resource and the operational arm of an
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TABLE 1 Components of Successful CF NBS Programs
NBS System CF NBS Program Speciﬁc Component
Prescreen
Inform family (brochure)
Prenatal distribution
Neonatal distribution
Educate health care providers Notice of CF NBS inclusion; grand rounds presentation; encourage
consideration of CF diagnosis in screened children with symptoms
Quality specimen collected
Quality specimen transported
Screen
Laboratory analysis Blood spot testing algorithm chosen, considering:
Spectrum of CF disease to be identiﬁed
Resources available
Sweat-testing services
Genetic counseling (when applicable)
Quality control
Data integration/integrity
Postscreen contact with PCP
Every infant: notiﬁcation Integration with existing systems
Positive screen result
Deliver report to PCP Materials for PCP on risk
Recommend next steps Materials for PCP on recommendations
Request repeat test; or Contact information for sweat testing and clinical evaluation;
materials to supplement report to subspecialist
Recommend subspecialty referral
Track to assure next step
Negative screen result but clinical concern
Deliver report to inquirer
Educate inquirer on next steps Materials for PCP on risk and recommendations
Prediagnostic test contact with parent
Positive screen result
Deliver report to parent
Educate parent Materials for PCP to use/hand to parent including description of sweat
test
Schedule subspecialty referral Speciﬁcs of CF center location; work to ensure rapid referral
Negative screen result but clinical concern
Educate parent Materials for PCP to use/hand to parent
Schedule subspecialty referral
Diagnostic evaluation
Evaluation Infection control
Interpretation Deﬁne positive, negative, and borderline sweat-test results for NBS
program
Case deﬁnition of CF
Postdiagnostic test
Report outcome to parent, PCP, and NBS Materials on positive, false-positive, and ambiguous results and
mechanisms for reporting
Positive diagnosis Infection control and care guidelines
Intake by subspecialty care
Education
Equivocal diagnosis
Follow-up plan Infection control; follow-up and care
Education
Negative diagnosis Genetic or posttest counseling
Education
Release
Quality control Regular meetings between NBS core program and CF care centers
Tracking
Outcomes assessment
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overarching state NBS advisory committee,34 which
should include representation from a wider variety of
stakeholders including parent advocates, primary care
professionals, staff from birth hospitals with obstetrical
services, and insurers. All members of the CF NBS work-
group will have to become familiar with the various
elements of a CF NBS program (Table 1). For each ele-
ment, the workgroup must determine the extent to
which (1) the basic standard of care is followed or ex-
ceeded, (2) compromises resulting from sociogeographic
or socioeconomic considerations are incorporated, and
(3) data are collected for quality improvement and re-
search purposes.
Among the first tasks of the CF NBS workgroup
should be to determine the spectrum of CF disease that
the program will aim to identify. A successful CF NBS
program must balance the desire to identify all infants
with CF, whose disease can vary from extremely mild to
severe, with the realities of subjecting large portions of
the population to diagnostic tests and limited resource
TABLE 2 CF NBSWorkgroup Topics for Successful CF NBS Programs
Component Action Considerations
Screening algorithm Deﬁne goals for disease detection Responsibility of NBS program
Select CF case deﬁnition relative to program goals Responsibility of CF Workgroup
Does program aim to identify only infants with classic CF,
or those with mild/variable CF also?
Develop algorithm Does NBS program collect 1 or 2 specimens?
IRT/IRT Projected numbers of true/false-positive results; true/
false-negative results; need for sweat tests
IRT/DNA Projected numbers of true/false-positive results; true/
false-negative results; CF carriers; need for sweat
tests, genetic counseling
F508 only What are the allele frequencies in population served?
Mutations associated with severe disease
Mutations associated with severe or variable disease
Prescreen education
Lay community Develop resources for families Responsibility of NBS program
Medical community Responsibility of NBS program
Develop resources for PCPs
Develop presentation for grand rounds Presentation by members of CF workgroup
Postscreen reporting Responsibility of NBS program
Positive result Develop materials for reports
Develop checklists for telephone report and
recommendations to PCP
Issue reports and recommendations
Fax conﬁrmation of details in writing
Negative result Develop materials and fact sheets for report Include written reminders
Issue reports Need to sweat test any infant with MI or other clinical
signs of CF
Recommend sweat test for any infant with CF-speciﬁc
clinical concern
Negative result does not rule out carrier status
Diagnostic evaluation Sweat test is gold standard All infants with a positive NBS result need sweat test
(regardless of parental carrier testing or NBS result)
All infants with clinical concern for CF should have sweat test
Recommended site: CF care center with infection
controls
Deﬁne positive, negative, and borderline values
Genetic counseling
On same day as sweat test, or
As a follow-up appointment
Quality control: tracking and
outcomes assessment
All sweat-test results for NBS-positive infants should be
reported to the NBS program
Centralized tracking by NBS program allows for quality
improvement, detection of unanticipated risks, and
Extended DNA results should be reported to the NBS
program
continuing modiﬁcation and evaluation of the program;
CF clinician from care centers recommended to act as
Any discordant result should be reported to NBS program (2
severe mutations detected and negative sweat-test
result; discordant genotypes)
liaison with NBS program
Any positive results of sweat testing resulting from clinical
concerns should be reported to NBS program (false-
negative results)
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availability. The CF NBS workgroup should determine
the resources available and develop a screening algo-
rithm that will optimize the use of these resources to
identify those infants who are likely to receive the great-
est benefit. Some states may choose to identify infants
with all possible CF indications, because even mildly
affected infants may experience life-threatening salt
loss,35 although this is rare. Such decisions also increase
the likelihood of identifying infants who either will not
develop any CF symptoms or will only develop mild
symptoms later in life. Other programs, with more lim-
ited resources, may choose to focus on a subset thought
to have a prognosis of severe disease.
Finally, the CF NBS workgroup should ensure that all
necessary guidelines for systems and care are in place
before CF NBS implementation. A manuscript detailing
the protocol for care of the newborn diagnosed with CF
through NBS is under preparation by the CF Founda-
tion.
SPECIFICATIONS FOR SUCCESSFUL CF NBS PROGRAMS
Prescreen Education
In addition to the standardized educational materials
distributed by NBS programs to expectant parents and to
parents immediately after the birth of their infant, the
following types of CF-specific information should be
developed or accessed for distribution:
● Notice to parents of availability of CF NBS: Typically
coordinated by the state NBS program, this notice may
be in the form of public service announcements, fly-
ers, and educational materials distributed to prenatal
services and educational brochures distributed to
nurseries. Notices that reach parents prenatally may
help them understand that prenatal and neonatal
screening services are different and that both are avail-
able.
● Notice to pediatric health care providers of CF NBS:
This task is usually coordinated by the state NBS pro-
gram. A model notice, incorporating some educational
material about CF, is shown in Appendix 1. Alterna-
tively, notification may be in the form of a “legal
notice” or public service announcement, especially if
the state is adding several disorders to its screening
program at once. Proper education of the primary care
community is helpful in accomplishing the objectives
of the CF NBS program and diminishing misunder-
standing about the abilities and limits of the screen.
Although state-of-the-art screening will identify 96%
to 99% of CF-affected infants,36–38 false-negative re-
sults could cause a significantly delayed diagnosis be-
cause of complacency of the PCP, who may ignore
clinical signs of the disease.25 Regardless of CF NBS
results, diagnostic evaluation including sweat testing
should be performed on any infant who evokes clin-
ical concern, including all infants with meconium il-
eus (MI), and any infant whose parents are both car-
riers.
● Standardized presentations: These should be devel-
oped by the CF NBS workgroup to ensure that the
information being provided in local educational sem-
inars for physicians about CF NBS is accurate and
representative of the protocol developed by the CF
NBS workgroup. It is helpful when health care pro-
viders can be assured by the presenter that consulta-
tion with the CF NBS program is available in the event
of a positive screening result, providing them with a
support system.
These and other educational materials designed for
CF NBS are available in those programs that have al-
ready initiated screening programs (see Table 3 and Ap-
pendices 1–3).
Blood Spot Testing Algorithms for CF NBS
All screening algorithms in current use in the United
States rely on testing for immunoreactive trypsinogen
(IRT) as the primary screen for CF.39 The presence of
high levels of IRT, a pancreatic protein typically elevated
in CF-affected infants, indicates the need for a second
tier of testing, which determines the positive or negative
outcome of the screen. The second-tier test may rely on
IRT again or DNA testing; within these 2 categories, a
variety of modifications are used40 because no single
algorithm is perfect. For example, 2 different algorithms
using DNA in the second tier could eventually identify a
similar number of affected infants; however, one algo-
rithm that tests for more Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) mutations might result
in quicker diagnosis and allow for earlier intervention,
whereas the other might identify fewer carriers. In
choosing an algorithm, consideration should be given to
the goals of the program, the demographics of the pop-
ulation to be served, and the capacities of the screening
laboratory, the clinical care programs, and the follow-up
system. The incidence, prevalence, and (for algorithms
using DNA) mutant allele distribution must be estimated
to determine if facility and personnel needs resulting
from a particular screening algorithm can be met. In
considering these needs, it is useful to realize that an
early diagnosis is important, but hours or days are not as
critical in identification of CF as in that of several other
standard newborn-screened disorders such as galac-
tosemia or congenital adrenal hyperplasia.
IRT Analysis: A Cautionary Note
Because newborns with CF and MI may have low initial
IRT values,41,42 resulting in a false-negative screen, all
newborns with MI should have a sweat test regardless of
NBS results. In contrast, infants who have significant
perinatal stress or low Apgar scores or (as observed in 1
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study) are black may display high IRT values, resulting in
false-positive newborn screen results.36,43 The urgency
associated with the report or follow-up protocol for in-
fants with these risk factors may need modification.
IRT/IRT Algorithms
The choice of screening algorithms will be driven par-
tially by whether the community NBS program rou-
tinely and universally collects 2 specimens or only a
single specimen. If 2 specimens are universally collected,
the community has the option to assay IRT in both
primary and second-tier tests on specimens collected at
2 days and then again at 14 days of age (IRT/IRT
algorithm). Use of an IRT/IRT algorithm avoids the iden-
tification of large numbers of CF carriers from DNA
analysis and the associated needs for genetic counseling.
However, if only a single specimen is routinely collected,
use of an IRT/IRT algorithm would require a specific
request for a second sample and an acknowledgment
that the first specimen screen result was positive. Be-
cause IRT levels decrease after the first weeks of life, the
timing of sample collection is important and laboratory
cutoffs for age-specific ranges must be established. In
keeping with routine laboratory quality assurance, cut-
off levels must be determined by each NBS laboratory to
meet the desired sensitivity and specificity of the screen
and should be evaluated periodically. Some laboratories
may choose to use an absolute IRT value for a cutoff,
whereas others may identify a percentage of the daily
values as the cutoff.44 The latter method avoids the prob-
lem of seasonal variations in IRT values that may be
caused by lability of the sample during shipment to the
processing laboratory45 but may be more subject to vari-
ation as a result of daily population shifts.
IRT/DNA Algorithms
Some CF NBS programs may prefer to use a screen that
includes DNA analysis. In fact, if the NBS program col-
lects only a single specimen universally, then an algo-
rithm with IRT as the primary screen followed by a DNA
analysis on the specimens with elevated IRT concentra-
tions (IRT/DNA algorithm) is typically chosen. The IRT
cutoff that is selected to prompt DNA testing is a factor in
producing false-positive and false-negative results that
must be considered by the CF NBS workgroup.
Use of DNA analysis in the second tier of screening
necessitates the selection of mutations in the CFTR gene
for testing. A decision can be made to test for only the
most common CFTR mutation, F508; for F508 and
multiple mutations associated with severe disease; or for
a panel of multiple mutations that includes some vari-
ants associated with mild or variable phenotypes. This
decision must be based on a number of considerations,
including those that are philosophical (the purpose of
screening), scientific (current understanding of geno-
type-phenotype relationships), clinical utility (benefit to
the infant and family), and practical (cost, system capac-
ity for increased numbers of positive-screened infants).
The choice of whether to use a multiple-mutation
panel or an assay for F508 alone is the first consider-
ation. The frequency of F508 in the community will
help determine the usefulness of a single-mutation assay
in the second tier of the screen. In the Massachusetts CF
NBS program, the use of a multiple-mutation panel
(16–27 mutations) rather than just the single most com-
mon mutation increased the detection of affected infants
by 50% and reduced the false-negative rate fourfold,
although it also increased detection of carrier false-pos-
TABLE 3 Educational Materials for CF NBS
1. The New England Regional Genetics Group has materials available for
purchase at www.nergg.org/educationmaterial.php, including:
A listing of state genetic programs, comprehensive genetic counseling centers,
and consumer support organizations
Optimizing Genetics Services in a Social, Ethical, and Policy Context, a booklet on a
discussion of what consumers want, a set of detailed suggestions for
responding to ethical problems in genetics, and a description of measures
to optimize interactions between consumers and providers in clinical
settings
Optimizing Genetic Services: Consumers Speak Out, a video that describes in
personal terms the highlights of what both consumers and providers
agreed should be part of optimal genetics services
2. The New South Wales Newborn Screening Programme has a parent/caregiver
fact sheet available at www.chw.edu.au/prof/services/newborn/factsheets/
cysticﬁbrosis.pdf
3. The Wisconsin NBS program has materials
Describing CF NBS for families (includes a video) (available at
www.pediatrics.wisc.edu/patientcare/cf/newborn.html)
For the families of CF carriers (available at www.slh.wisc.edu/newborn/
brochures/b3p1.html)
4. The New York State Department of Health has materials for families and PCPs
available at www.wadsworth.org/newborn/cfeducate.htm
5. The Nebraska NBS program offers
Materials for parents
CF fact sheet, available at www.hhs.state.ne.us/hew/fah/nsp/NewDocs/
ParentsPage/CFFactSheet.pdf
CF carrier fact sheet, available at www.hhs.state.ne.us/hew/fah/nsp/
NewDocs/ParentsPage/CFCarrierFactSheet.pdf
Initial positive result, available at www.hhs.state.ne.us/hew/fah/nsp/
NewDocs/ParentsPage/CFparentfactsheetInitialPositive.pdf
Initial inconclusive result: repeat recommended, available at www.hhs.state.
ne.us/hew/fah/nsp/NewDocs/ParentsPage/CFparentfactsheetInitial
Inconc.pdf
Initial inconclusive result: sweat test recommended, available at www.hhs.
state.ne.us/hew/fah/nsp/NewDocs/ParentsPage/CFparentfactsheet
InitialInconcSweatTest.pdf
Repeat positive result, available at www.hhs.state.ne.us/hew/fah/nsp/New
Docs/ParentsPage/CFparentfactsheetRepeatPositive.pdf
Repeat inconclusive result, available at www.hhs.state.ne.us/hew/fah/nsp/
NewDocs/ParentsPage/CFparentfactsheetRepeatInconc.pdf
Materials for PCPs
CF ACT sheet (recommended next steps when a positive or abnormal result
is reported for one of your patients), available at www.hhs.state.ne.us/
hew/fah/nsp/NewDocs/MDPage/CFACTSheet.pdf
CF information (more speciﬁc disease information), available at www.hhs.
state.ne.us/hew/fah/nsp/NewDocs/MDPage/CFINFOSheet.pdf
6. The Washington State NBS program offers materials for families and PCPs at
www.doh.wa.gov/EHSPHL/PHL/Newborn/reports.htm#CF
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itive results by 43%.36 In other communities, the choice
of using a single mutation in the second tier of the screen
may adequately meet the needs set forth by that state’s
CF NBS workgroup.
The selection of mutations for a multiple-mutation
panel can pose challenges, including:
● Reagent availability: Most NBS programs will use
commercially available reagents, which have largely
been developed for prenatal testing. However, these
reagents are not completely compatible with CF NBS,
because the goal of prenatal testing is detection of
parent carriers rather than detecting infants with CF.
Recently, commercial reagents that allow flexibility in
selecting mutations for testing have come onto the
market and will allow development of NBS- and pop-
ulation-specific instruments.
● CF genotype variation: Ideally, the mutation panel for
screening should be based on the frequency of CF
mutations present in the state CF population. A list of
CF genotypes and frequencies observed in the CF care
centers serving a community can be obtained from the
CF Foundation. However, measurement of CF geno-
types in nonnewborn clients of CF clinical care centers
can only approximate the frequency in the newborn
population. The validity of using these frequencies is
limited as a result of issues that include ascertainment
bias of CF in nonwhite populations, the extent of the
CF population genotyped, population shifts, and the
pattern of genotypes associated with diagnoses in
symptomatic infants.
● Genotype/phenotype relationships: Some CFTR muta-
tions, particularly those in classes IV (such as R117H)
and V (such as A455E or 3849  10 kb C3T or
IVS8-5T) (see the Cystic Fibrosis Mutation Database
[www.genet.sickkids.on.ca/cftr]) may be associated
with milder phenotypes,46 and the benefit from
screening algorithms that include these mutations has
not been proven. Longitudinal epidemiologic data on
individuals with classes IV and V mutations are quite
limited, particularly with regard to lung disease, and
few studies have included enough patients with a
comprehensive analysis of outcome.47 Inclusion of
DNA variants with undocumented pathogenicity in
NBS mutation panels risks the detection of asymptom-
atic infants who may have late-onset mild disease for
which the clinical utility of NBS is unproven and who
may also incur insurance barriers. Projections of the
rates of false-negative screens should be considered in
relation to the specific objectives of the CF NBS pro-
gram in making a decision to exclude these mutations
from a screening panel. Use of these mutations in NBS
is considered in more detail in “Special Consider-
ations” below.
Fail-safe for IRT/DNA Protocols
Some NBS programs may choose to define the presence
of ultrahigh IRT levels as a positive CF NBS result re-
gardless of DNA-analysis results. The Massachusetts NBS
protocol uses ultrahigh IRT values (eg, the top 0.2% of
the population values,36 recently raised to the top 0.1%)
as a fail-safe protocol to identify infants with CF who
have mutations that are not detected by the multiple-
mutation DNA panel. To increase specificity of this fail-
safe protocol, the IRT values of serial specimens are
evaluated when infants have multiple samples submit-
ted; if the value decreases to within reference levels
within the first month of life, the infant is excluded from
the recommendation for a sweat test.36 Because high IRT
values are associated with multiple causes, some NBS
programs may not consider ultrahigh IRT levels as a
positive screen result.48 In California, the proposed CF
NBS algorithm depends on a regionally customized DNA
panel to maximize sensitivity and specificity of the new-
born CF screen. In this algorithm, an IRT-level cutoff of
98.4% and at least 1 DNA mutation detected is projected
to produce 661 sweat-test referrals, revealing 70 diag-
nosed cases of CF. Although including ultrahigh IRT
levels with no DNA mutations in the positive screen
results is projected to detect 2 additional infants with CF,
it would also increase the number of sweat-test referrals
by an additional 426 and, therefore, is not incorporated
into the algorithm (M. Kharrazi, PhD, MPH, written
communication, 2005). However, when the California
algorithm was examined by retrospective application to
the 110 CF-affected infants identified from a 4-year Mas-
sachusetts birth cohort,36 12 (11%, including 4 F508
homozygotes) would have been missed by the 98.4%
IRT-level cutoff, and another 3 (3%) would have been
missed by the requirement for detection of at least 1
mutation (A.M.C., unpublished data). This would have
been outside the 95% detection rate that the Massachu-
setts program set as its goal.
Each CF NBS workgroup must decide whether the
community it represents will receive more benefit from
such fail-safe protocols or from protocols that require
development and maintenance of population-specific
mutation panels for potentially changing populations.
Summary
States that wish to start a CF NBS program may use
IRT/IRT algorithms or IRT/DNA algorithms. Those
adopting the latter may wish to begin developing pro-
jections of positive screen results by using the DNA-
mutation frequencies identified in the CF Foundation’s
patient registry and then expanding the data to reflect
the population subgroups in that state. Screening algo-
rithms that include class IV and V mutations have been
used in recent years, but additional data are needed to
determine their appropriate role in CF NBS. As with all
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NBS programs, a balance must be struck between sensi-
tivity, specificity, and clinical utility.
Postscreening Report and Education
The responsibility for finding and notifying the PCP of
the infant with a positive CF screen result is typically
that of the state NBS program or its associated maternal
and child health bureau, although models exist in which
the CF care center or the birth hospital is assigned to this
role (Table 4). Because these processes can be very labor
intensive, adding a large burden to the reporting system,
lines of responsibility and available resources should be
well defined before CF NBS implementation.
Positive CF NBS Report
In keeping with the overall NBS notification and report-
ing practices, the designated follow-up person from the
CF NBS program should identify the PCP, notify that
person of the positive screen result, and recommend that
the infant be given a sweat test. Ideally, the PCP will be
contacted by telephone, followed by timely confirmation
of details in writing (eg, fax reports).49 The CF NBS
follow-up person should be prepared to explain the
screening process and the risk of CF for the particular
infant and provide contact information for diagnostic
evaluation while collecting information as to the likely
preferred site for this evaluation. The educational mate-
rials that are used to introduce CF NBS (Appendix 1) can
be used to refresh and update general information to the
health care provider. Other materials, aimed at explain-
ing the CF newborn screen to the public, can be provided
to the health care provider to give to the family (Appen-
dix 2).
Family counseling before the sweat test typically be-
gins with the PCP and may or may not be offered again
at the CF care center. In the event that the PCP is not
comfortable providing this information or is unavailable,
the CF care center may need to assume this responsibil-
ity. After obtaining a complete family history, the coun-
selor should be able to:
● explain the CF NBS process;
● provide a general description of CF;
● explain the positive CF NBS result and its implications;
● relate the relative risks of a positive, negative, border-
line, or insufficient-quantity sweat-test result and risk
of a positive or equivocal diagnosis associated with the
individual report, including less typical reports such as
an ultrahigh IRT level with no identified mutations;
● provide the location of the diagnostic evaluation;
● describe the services (sweat testing, nursing, genetic
counseling) and personnel the family can expect to
encounter at the diagnostic-evaluation visit;
● form a plan for follow-up of the sweat-test result; T
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● explain the significance of the presence of a single
CFTR mutation, if relevant, for future reproductive
decision-making for both the child and other family
members, including parents and siblings,30 and ar-
range for testing of the parents and family members if
desired; and
● provide educational materials that can answer some of
the family’s questions.
Once the site for diagnostic testing has been identi-
fied, the follow-up person should provide detailed
screening reports to the diagnostic site and the genetic
counselor, if applicable. Efficient scheduling and com-
munication with the sweat-test laboratory, genetic
counselors, and clinicians will be promoted if an indi-
vidual at the diagnostic center is identified to receive the
CF NBS report and coordinate the follow-up evaluation.
Negative CF NBS Report
A negative result generated by a routine CF NBS may be
reported in a manner that is consistent with overall
NBS-program practice and in conjunction with routine
reporting of other NBS tests. However, if clinical concern
has prompted a request for the newborn screen result by
the PCP, the CF NBS follow-up person should provide
NBS results within the context of recommendations for
diagnostic evaluation that are appropriate for each
unique set of circumstances. Timely response to such
inquiries, especially at the beginning of implementation,
helps educate the medical community. Sample fact
sheets to accompany the CF NBS report in response to
these inquiries are provided in Appendix 3.
Diagnostic Testing of Infants After a Positive CF NBS Result:
The Sweat Test
Confirmatory sweat tests are the gold standard for diag-
nosis and should be conducted on all infants with a
positive NBS result, including those with 2 mutations
detected. A positive screen result is not a diagnosis and
should always be confirmed by a diagnostic test. Infants
with a positive screen result whose mother or father had
negative carrier-testing results are at lower risk of having
CF, but their elevated IRT value must be investigated by
sweat testing.
Sweat-Test Laboratory Qualifications
The diagnostic quantitative pilocarpine iontophoresis
sweat-chloride test should be performed according to the
Clinical and Laboratory Standards Institute (CLSI, for-
merly the National Committee for Clinical Laboratory
Standards) guidelines at a College of American Patholo-
gists–accredited laboratory,50 as recommended by the CF
Foundation. Optimally, the testing should be performed
at a laboratory in affiliation with a CF Foundation–
accredited care center, where the test can be coordinated
with timely and appropriate genetic counseling and clin-
ical follow-up. If the sweat-test result is positive, it is
helpful for a CF clinician to be available for immediate
intervention. A CF clinician can also help with interpre-
tation of a complex diagnostic profile such as a border-
line or negative sweat-test result in the presence of 2
CFTR mutations. Access to a genetic counselor and CF
clinician is also helpful if there is a family history of CF,
a genotype requiring literature review, or information
on sensitive issues such as misattributed paternity. In
addition, because infants with CF could be subjected to
health care–acquired infection during their diagnostic
evaluation or early treatment,23 testing and clinical care
should take place at sites where this risk is recognized
and rigorous CF infection-control guidelines are fol-
lowed carefully.51 Ideally, the sweat test should be avail-
able within 2 to 3 hours’ driving distance for the family.
In regions where greater distances are unavoidable, it
may be necessary to establish CLSI guideline–proficient
satellite laboratories at which sweat can be both col-
lected and tested or collected and sent to a College of
American Pathologists–approved laboratory for analysis.
Although not ideal (as shown in one non-US study),52,53
such arrangements could ensure acceptable testing stan-
dards and may prevent long delays in testing as well as
provide a safe alternative for situations when long trips
are difficult.
Minimum Age and Weight of the Infant for Valid Sweat
Testing
Sweat electrolytes are high on the first day of life, but by
the third day they have declined to levels seen outside
the newborn period.54 The CLSI guidelines permit sweat
testing after 48 hours of age. Because CF NBS results are
unlikely to be available before 48 hours, the threshold
for sweat testing is more likely to be related to weight
rather than age; infants weighing 2 kg are more likely
to provide insufficient sweat for analysis (quantity not
sufficient [QNS]).
Other infants are also at increased risk for invalid test
results as a result of generation of insufficient sweat.
Premature infants or infants who are black exhibit a
higher frequency of QNS reports.43,55,56 Newer methods
of conductance determination on microsamples have
been developed but are not yet adequately standardized.
Because waiting for the sweat test to be performed leads
to family anxiety,37 the test should be scheduled as soon
as possible and parents should be informed of the risk of
QNS. Sweat testing is not considered an emergency, but
guidance by a CF specialist should be available for the
PCP at all times.
Diagnostic Interpretation After the Sweat Test
The following guidelines are designed to help CF NBS
programs develop follow-up protocols that (1) resolve
the outcomes of the vast majority of infants with positive
CF NBS results and (2) ensure monitoring of the small
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subset of infants whose diagnostic status cannot be re-
solved without additional guidance. A planned CF Foun-
dation–sponsored workshop will update the published
consensus case definition of CF57 and may provide assis-
tance in addressing some of these diagnostic dilemmas.
Regardless, it is most helpful to have specific diagnostic
protocols developed by the state CF NBS workgroup in
place before implementation so that the lines of action
and responsibility are clear.
Positive Sweat-Test Result
In keeping with CLSI guidelines, sufficient quantities of
sweat yielding chloride (Cl) values of 60 mEq/L is
considered diagnostic for CF.50 Exceptions to this rule are
familiar to clinicians who practice at CF care centers.58,59
Negative Sweat-Test Result
In the absence of significant clinical concern for CF, a
negative sweat-test result (Cl value of 30 mEq/L at
6 weeks of age) confirms a negative diagnosis. Clinical
signs and symptoms consistent with CF or the detection
of 2 pathogenic mutations in the CF newborn screen
should result in reexamination of the diagnosis by a
qualified CF clinician.
Borderline Sweat-Test Result
In older children and adults, a sweat Cl value between
40 and 60 mEq/L has been termed ambiguous or “bor-
derline” and is not clearly diagnostic. However, results
from several NBS programs indicate that newborns with
CF from 1 to 6 weeks of age tend to have sweat Cl
levels lower than those found in older infants and chil-
dren with CF.55,60 Thus, some screening programs rec-
ommend that a lower limit of 30 mEq/L (still 5 SD above
the normal mean61) be adopted as the lower limit of the
borderline range in infants. In Massachusetts, lowering
the cutoff from 40 to 30 mEq/L resulted in an increase
from 1.1% to 3.5% in the number of screen-positive
infants with a borderline sweat-test result, who then
required additional monitoring before diagnostic resolu-
tion (A.M.C., unpublished data). Evaluation of any in-
fant with a borderline sweat-test result should include
repeat sweat testing scheduled for a later date. If 2 CFTR
mutations were detected by the newborn screen, a CF
specialist should be consulted to determine the appro-
priate next steps. If 1 CFTRmutation was detected by the
screen, a genetic counselor should be consulted to de-
termine if an extended panel of CFTR mutations should
be used in additional testing.62
For more detailed discussion of recommendations af-
ter borderline sweat-test results, see “Diagnostic Dilem-
mas: Borderline Sweat-Test Results” under “Special
Considerations” below.
Communicating Diagnostic-Evaluation Results to the Parents
CF NBS is optimized by effective communication of di-
agnostic results, including well-developed counseling
and education resources.23,29,30,63–65
Positive CF Diagnosis
When the CF NBS result indicates a high likelihood of
CF, the NBS program should alert the clinical care center
to allow the parents to meet with a CF clinician at the
time of the sweat-test visit. Ideally, the parents of any
infant with a positive sweat-test result should be able to
meet with a CF clinician before leaving the clinical care
center. The CF clinician should be prepared to discuss
the diagnosis, prognosis, immediate next steps for the
parents, and a short-term plan that includes a visit to
meet with the CF team, which will coordinate care with
the infant’s PCP. Presentation of these recommendations
in writing is helpful.
In some cases, particularly at laboratories that expe-
rience a low volume of sweat testing, parents will leave
before results become available. A report of the diagnosis
is then made, ideally, by a CF specialist to the PCP, who
will be the primary route of communication to the par-
ents. The PCP should have adequate information (or
telephone numbers of relevant CF care centers) to ad-
dress initial parent concerns and should facilitate the
scheduling of a follow-up appointment with the CF
team. For families of infants with a positive CF diagnosis,
sweat tests should be arranged for all first-degree siblings
and for any half-siblings who have signs or symptoms of
CF or who have 2 parents known to be carriers.
Negative CF Diagnosis
As is characteristic of all NBS, most infants with a posi-
tive CF NBS result will not have CF. Because families of
infants with “false-positive” screen results (in which the
screening result is positive and the diagnostic sweat test
is negative) will have no continuing support from the CF
care center, sympathetic and accurate transmission of
information to allay future concerns takes on a high
level of importance.
● For a positive screen result that shows no mutations,
counseling may be offered by the PCP or the CF care
center; no genetic counselor is required. Because the
combined screening and diagnostic-test results indi-
cate that the infant is unaffected, with no detected
mutation, this counseling should convey the under-
standing that there is no increased risk of CF but that,
as with all children, significant clinical signs should be
evaluated. Possible explanations for the elevated IRT
level such as low birth weight or Apgar score, prema-
turity, or race should be discussed.
● For a positive screen result that shows 1 mutation,
counseling is optimally offered by a certified genetic
counselor or CF clinician. Because the combined
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screening and diagnostic-test results indicate that the
infant is an unaffected carrier with at least 1 parent
carrying a CF mutation, parent counseling should ad-
dress the risk to their future pregnancies and whether
the parents wish to undertake their own carrier test-
ing. Implications for other family members should also
be discussed, and the PCP should be informed that all
first-degree siblings who display potential symptoms
should have a sweat test performed. The carrier status
of the infant should be kept available in the infant’s
medical chart and, ideally, will be discussed with the
individual when reproductive age is reached.
Insufficient Sweat for Analysis (QNS)
When a diagnosis cannot be made because of insufficient
sweat collected, a person must be designated to commu-
nicate the QNS result and schedule the follow-up visit. If
the parents have already been scheduled for a genetic
counseling session during the same visit, the genetic
counselor can help explain the report. If the parents
have left the center before the QNS report or if genetic
counseling was not scheduled, the PCP should be the
designated liaison with the family.
Diagnostic Dilemmas
Ideally, the primary communication of an inconclusive
evaluation and its meaning relative to the specific clini-
cal situation is delivered by a CF specialist to the parents.
When the PCP must deliver a complex communication,
they should facilitate scheduling a follow-up with a CF
specialist as indicated by the specialist; families need to
be counseled about phenotypic variability associated
with specific genotypes66 with relevant and accurate in-
formation about atypical or complex results.
Ambiguous diagnostic tests, discordant diagnostic
tests, or inability to complete diagnostic tests heightens
anxiety by prolonging the time to resolution of the pos-
itive screening result. In some instances, ambiguous di-
agnostic-test results may be caused by the presence of a
“variant” of CF that places the family in a prolonged
period of diagnostic uncertainty without a clear compen-
sating benefit attributable to the screen or the evalua-
tion.60,67,68 Ultimately, some of these infants may show
classic signs of CF, some may never express disease, and
some may develop mild phenotypes (eg, isolated con-
genital bilateral absence of the vas deferens) so that the
interventions prompted by CF NBS might have limited
clinical value. Debate continues on the appropriateness
of identifying, labeling, following up, or treating infants
in the absence of a clear understanding of the prognosis
of their particular disorder. Information gained from
ongoing experience should help improve decision-mak-
ing in choosing screening algorithms that meet NBS-
program goals for level of disease to be detected.
Genetic Counseling
Genetic counseling is a necessary and vital part of fol-
low-up care for parents of children who have a CFTR
mutation revealed by a positive CF NBS result. Studies
have demonstrated that psychosocial sequelae of false-
positive NBS results can occur, including those resulting
from CF-carrier identification.69,70 Genetic counseling
promotes understanding of the results and offers parents
an important venue for psychosocial support and for
addressing implications regarding reproductive choices
for themselves and other family members.71
Some states ensure that parents of screen-positive
newborns have access to genetic counseling at CF care
centers on the day of the sweat test.29,30 Same-day coun-
seling may be provided before sweat testing, while par-
ents await results, or (optimally) after results of the
sweat testing are available. However, availability and
funding of genetic counseling services varies. Some CF
care centers offer genetic counseling on the day of the
sweat test, and others inform families that they may
speak with a genetic counselor at a later date.72 (Note
that genetic counselors who practice at a children’s hos-
pital should ensure that the parents’ PCPs are included
in decisions about any parent testing.) Scheduling the
genetic counseling with the sweat test ensures transmis-
sion of information to the parents and allows knowl-
edgeable caregivers to address the parents’ immediate
concerns about their child’s health and begin to establish
a relationship with the family of a child with a positive or
borderline sweat-test result. However, trying to coordi-
nate sweat testing together with a genetic counseling
appointment may result in some delay. In addition, pro-
viding counseling on a subsequent day might result in
longer-lasting understanding of the newborn screen re-
sults and family risk if the parents’ acute anxiety from
the sweat test has dissipated. On the other hand, offering
genetic counseling on a separate day may result in a lost
opportunity for counseling if parents cannot or do not
return;70% of families who were offered separate-day
genetic counseling in a Massachusetts NBS program
never accessed the service.73
Providers of genetic counseling related to CF NBS
should have training in genetics and experience with
caring for patients with CF to ensure that families re-
ceive complete care. The family’s emotional needs
should be addressed in a culturally sensitive manner,74
and risk assessment should include available informa-
tion on families of similar ancestry.75 For example, in the
families of infants who are identified as CF carriers, a
parent who carries the CFTR mutation has been shown
to have increased anxiety/guilt as compared with a par-
ent who does not carry a CFTR mutation.31 It should be
explained that the carrier parent’s subsequent pregnan-
cies and those of relatives are at an increased risk for CF,
relative to the general population. In a small percentage
of cases, both parents are carriers, although the screen-
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positive newborn inherited a mutation from only 1 par-
ent. These couples have a 25% chance that a previous
child has or subsequent child will have CF. Parental CF
DNA analysis can be offered to identify the carrier parent
and to distinguish the 1-carrier couple from the 2-carrier
couple. It is important to address this issue sensitively,
because parental testing can result in detection of mis-
attributed paternity.
Several states use multiple-mutation panels, which
increase the number of carriers identified by the screen-
ing process.36 The inclusion of alleles (such as R117H76
and I148T77) with inadequately understood effects ne-
cessitates detailed knowledge by the genetic counseling
provider so that parents are properly informed of their
child’s diagnostic or carrier status and are provided with
correct information regarding their chances of having a
child with CF in the future.
Quality Assurance of CF NBS: Tracking and Outcomes
Assessments
CF NBS is beneficial only if infants identified by the
screen receive a prompt diagnostic evaluation. The re-
sponsibility for tracking the infant to assure compliance
with the recommendation for evaluation and to docu-
ment diagnostic outcome is typically that of the state
NBS program or its associated maternal and child health
bureau. To enable proper data collection and facilitate
this tracking, the following must be reported to the state
NBS program:
● diagnostic outcome on all NBS-positive infants;
● any CF diagnosis on an individual who was screened
by CF NBS regardless of the screening result; and
● any diagnostic result that is discordant with the result
of the CF NBS (eg, a negative sweat-test result [30
mEq/L] in an infant whose NBS showed 2 severe CF
mutations).
● In some models, additional data are collected for long-
er-term outcomes assessments as a measure of the
clinical utility of the overall program. Collection of
outcomes data for such purposes constitutes human-
subjects research, and protocols should be reviewed by
appropriate human-subjects research boards. Out-
comes assessments will help quantify the benefits of
new approaches or treatments and help detect unan-
ticipated risks such as the early acquisition of Pseudo-
monas, which occurred in 1 CF NBS trial.23 The track-
ing in that trial resulted in a critical clinical
recommendation to isolate newborns with positive CF
NBS results from other patients in the CF care center
to prevent serious health care–acquired infections.51,78
● CF care centers should report sweat and genetic test-
ing results to the state NBS centralized system for
cohort analysis, including cases in which CF is diag-
nosed in children with negative NBS results. False-
negative screen results caused by an IRT level below
the cutoff value, unidentified CFTR mutations, or hu-
man error can occur. In all cases, positive results of
sweat tests performed as a result of clinical concern
should be reported to the centralized NBS program.
This, in turn, facilitates continuing evaluation and
modification of screening algorithms and consider-
ation of unanticipated benefits and risks after the im-
plementation of CF NBS.
● The NBS program and the CF care centers need to
work carefully as a team to collect the necessary data
(Table 5); some data may need to be collected by both
groups. It is beneficial for the various care centers in
each state to work together to collect statewide infor-
mation for the ongoing evaluation of the NBS
program.
Financing CF NBS and Care
States fund NBS programs in a variety of ways.79 Many
states set and collect fees for screening, and many use
some public health funding to supplement fees. Spe-
cialty care after a diagnosis of CF is made is funded
similarly to that for children affected with other disor-
ders.
TABLE 5 Tracking Needed for Evaluation of Follow-up to CF NBS
Parental compliance with follow-up recommendations
1. Infants/families who complied with follow-up testing
2. Attempts at additional contact
3. Infants who were lost to follow-up
4. Dates of birth, NBS, and sweat test
5. Date of genetic counseling
Diagnostic effectiveness of screen
1. Infants born and infants screened (per month/year)
2. Infants given sweat test (recall rate)
a. Negative sweat-test results (false-positive results)
b. Positive sweat-test results (true-positive results)
c. Borderline sweat-test results (ambiguous diagnosis)
d. Failed sweat-test results (QNS)
3. Screen-negative children diagnosed with CF later via conventional
methods (false-negative results)
CF NBS algorithm sensitivity
1. False-negative results
a. Determine why the screen failed to detect CF
b. Determine whether the IRT cutoff and recall rates meet the stated goal
for sensitivity
2. CFTR genotypes of patients diagnosed with CF
a. Children diagnosed with CF through NBS
b. False-negative results
c. CFTRmutation panel used: does it meet the stated goal for sensitivity?
Management of care center protocols
1. Date the infant entered care at CF care center
2. Conﬁrmation of implementation of appropriate care plan for unique NBS
population
3. Conﬁrmation that data are provided to CF Foundation’s patient registry
including anthropometrics, cultures, hospitalizations, and complications
4. Conﬁrm offer and receipt of genetic counseling (when applicable);
documentation of obstacles to genetic counseling (time, lack of counselors,
reimbursement)
e506 COMEAU et al
 at UNIV OF MASSACHUSETTS on March 11, 2009 www.pediatrics.orgDownloaded from 
CF care centers must be prepared to receive referrals
from the screening program. Care centers and NBS-
program staff should work together, therefore, to predict
the number of infants who will screen positive and to
outline protocols for their follow-up. In states that use
IRT/DNA algorithms, the majority of screen-positive in-
fants who do not have CF will be carriers45; before ini-
tiating screening, the number of carriers expected should
be calculated to identify resources for the parents who
should be offered genetic counseling as well. From these
estimates, center directors can determine the resources
that will be needed for sweat testing, special profile
interpretation, genetic counseling, and clinical care for
infants who are determined to be affected.80
Sweat-testing facilities may see a change in the num-
ber of referrals and referral patterns as a result of popu-
lation-based CF NBS. In Wisconsin, the number of sweat
tests ordered decreased after CF NBS implementation,
presumably because of a decrease in sweat tests ordered
by the PCP for CF-like symptoms; consequently, the
number of facilities offering sweat testing was greatly
reduced.24 In Massachusetts, the number of sweat tests
increased when screening began and then diminished
somewhat,81 although PCPs still order a considerable
number of tests. CF care centers and NBS programs
should work together to predict the number of sweat
tests generated by CF NBS and decide where the tests
would be performed to plan for appropriate staffing,
while recognizing that sweat-test numbers may vary as
the screen is implemented.
Screening algorithms designed to detect the highest
number of infants with CF could overload resources
available for communication, sweat testing, and coun-
seling. Alternative screening plans may need to be con-
sidered if this results in long waits or travel times. Such
alternatives might include use of mobile sweat-test lab-
oratories that meet the same standards as those ap-
proved by the CF Foundation for standard sweat-test
laboratories, quality-controlled local sweat collection
that is then sent to a certified laboratory for analysis, a
change in screening algorithm, or teleconference coun-
seling.
Research Opportunities
CF NBS provides the opportunity and the responsibility
to conduct research to improve treatment and outcomes
in CF (Table 6). Epidemiologic/observational and thera-
peutic trials should be conducted. Because of the small
number of infants diagnosed at each site, research
projects will generally require multicenter collaboration,
and some studies will require centralized coordination at
the NBS-program level. NBS and early diagnosis may
accelerate the adoption of new treatments for infants
with CF, because it creates an opportunity to define a
specific cohort from early in life for entry into clinical
trials.
In addition to such clinical research, there must be
continual evaluation of outcomes resulting from the ini-
tiation of CF NBS (Table 7) based on current clinical
practices. This is a crucial step to maintaining high-
quality CF care for this new population and will also
help support the initiation and continuation of CF NBS
programs throughout the United States.
Special Considerations
Community-Customized Mutation Panel
Ideally, mutation panels for screening should be based
on the frequency of alleles present in the regional pop-
ulation. This can vary widely. In California, 50% of the
TABLE 6 Priorities for Future Research in Those DiagnosedWith CF by NBS
Epidemiologic/Observational Therapeutic Trials
Risk factors and outcomes associated with acquisition of Pseudomonas
aeruginosa, mucoid P aeruginosa, antibiotic-resistant P aeruginosa
Early antipseudomonal intervention
Antiinﬂammatory therapies
Outcomes associated with S aureus respiratory infection Improved nutritional approaches or therapies
Temporal association of early respiratory symptoms, Pseudomonas
serology, and respiratory cultures
Airway-clearance medications/techniques/chest
physiotherapy
Role of respiratory viruses in early CF lung disease
Effect of early diagnosis on infants with class IV and V mutations;
beneﬁt/risk assessment
Development of sensitive, easily obtained outcome measures in
infants with CF that correlate with disease progression
High-resolution computed tomography study of lung-disease
progression, exacerbations
Infant pulmonary-function tests
Symptom scoring
Health-related quality-of-life scales
Sweat-testing microtechniques compared to standard testing
approaches
Portable conductance testing compared to sweat Cl standards for
newborns
Nasal potential difference testing in infants
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530 000 live births are to Hispanic women, largely of
Mexican origin, and 6% are to black women,82 whereas
Massachusetts has a population that is 8% Hispanic and
8% black.83 The spectrum of CFTR mutation frequencies
varies in populations of each ancestry, and a large pro-
portion of CFTR mutations is still unidentified in His-
panic and black people. A recent study that used a 70-
and 86-mutation panel reported a detection rate of 62%
in black infants, 58% in Hispanic infants, 38% in Asian
infants, and 81% in Native American infants in the
United States compared with 85% in white infants and
95% in Ashkenazi Jewish infants.84 Identification of in-
fants with CF can be enhanced by choosing an appro-
priate mutation panel: a 75% detection rate can be
achieved in black populations by screening for 16 “com-
mon white” mutations and 8 “common African” muta-
tions.85 Differing detection rates are especially significant
in states like California, where 33% of the 70 infants
with CF projected to be identified each year without MI
are expected to be Hispanic and 2% are expected to be
black. In an attempt to detect at least 90% of newborns
with CF in the 3 main ancestral groups that include
Hispanic, non-Hispanic white, and black infants, the Cal-
ifornia Department of Health Services Genetic Disease
Branch has designed a model CF NBS algorithm using a
custom mutation panel developed from an analysis of
the allele frequency of a cohort of affected patients with
CF.86 When implemented, results from this screening
algorithm will contribute to our understanding of the
possible utility of customized population-based mutation
panels for CF NBS.
CFTR Mutations and Mild Disease
The panel of CFTR mutations that the NBS program
chooses for screening depends partially on the spectrum
of disease that the regional program decides to detect.
Because individuals with CF who have one class IV or V
mutation would almost always be identified through
detection of a class I, II, or III mutation on the other
chromosome,87,88 some NBS programs may choose not to
include class IV or V mutations in the screening panel.
Indeed, removal of the class IV R117H mutation from
the Massachusetts CF NBS panel would lower the false-
positive rate by 10% in that population (A.M.C., unpub-
lished results). However, the proposal to detect infants
with CF with a class IV or V mutation by relying on the
screen finding a class I, II, or III mutation from the other
chromosome also relies on those infants having an ele-
vated sweat Cl level. Some individuals with class IV and
V mutations can develop clinical symptoms89–93 even in
the absence of an elevated sweat Cl concentration.
Use of mutations associated with milder phenotypes
may lead to results that are difficult to interpret and
communicate in DNA testing of a family after positive
NBS results. Because some individuals with a genotype
including F508 and a class IV or V mutation may be
unaffected by CF,76 testing that uses these mutations
may best be limited to families of infants who are symp-
tomatic or have a positive sweat-test result.
Complex gene modifiers associated with disease ex-
pression of the IVS8-5T mutation (eg, TG repeats and
M470V polymorphism) have been identified,94,95 but the
intricacy of the testing is beyond the current scope of
NBS. Furthermore, although up to 20% of infants with
an elevated IRT level, one F508 mutation, and a sweat
Cl level of 40 mEq/L may possess 5T on the other
chromosome, none have a classic CF phenotype,96 which
suggests that the IVS8-5T DNA variant, at least, should
not be included in mutation panels used for CF NBS.
Diagnostic Dilemmas
Borderline Sweat-Test Results
Approximately 10% of newborns with CF that was
detected through NBS using current DNA-mutation
panels and diagnosed with CF by a CF clinician express
sweat Cl concentrations 60 mEq/L.28 Because sweat
Cl levels can change over time, tests resulting in a
TABLE 7 CF NBS Outcomes Research
Action Outcome Measures
Sweat test Proportion performed at accredited clinical laboratories
Changes in numbers of sweat tests conducted annually before and after implementation of
state CF NBS
Inconclusive results: number of QNS tests, number of borderline tests, genotype
relationship to sweat-test result
Genetic counseling
(when applicable)
Proportion of families of infants with positive screen result/negative sweat-test result (ie,
carriers) receiving genetic counseling
Proportion of families of infants diagnosed with CF through NBS receiving genetic
counseling
Impact on family knowledge and decision-making
Methods for presentation of genetic information to individuals with CF at age 18 y
CF care Proportion of diagnosed infants followed at CF Foundation–accredited care centers
Outpatient visit frequency
Inpatient hospitalization frequency
Computed tomography score results
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borderline result should be repeated in 1 to 2 months. In
the interim, the clinician should monitor nutritional sta-
tus and growth for any impact by possible pancreatic
insufficiency. Also, because individuals with CF and bor-
derline sweat-test results may be susceptible to respira-
tory disease regardless of pancreatic function, vigilant
monitoring for respiratory problems remains critical to
enable the early interventions that improve outcome.
A moderate percentage (17%) of infants with border-
line sweat-test results are found to possess 2 CFTR mu-
tations when extended mutation analysis is performed.60
Some mutations that occur in the borderline-result
group, such as 3849  10 kb C3T or A455E, are clearly
associated with a disease phenotype, and infants with
these mutations should be diagnosed with CF. When
R117H (7T) mutation is one of the 2 CFTR mutations,
diagnosis is more problematic because only some of the
individuals with this genotype develop signs and symp-
toms of CF88; evaluation of prospective data will help
clarify the role of this mutation in NBS.93 It may be
prudent to defer diagnosis of CF in these individuals but
continue follow-up at a CF care center so that the diag-
nosis can be made if symptoms appear. Newborns with
borderline sweat-test results who have only 1 or no
identified CFTR mutation and newborns who have 2
CFTR mutations with sweat Cl levels 30 mEq/L67
should be followed up similarly. This situation may be
complicated by the lack of commonly accepted protocols
for follow-up of infants in these groups. (Normal, bor-
derline, and abnormal sweat-test results with suggested
follow-up are discussed in more detail by Parad and
Comeau.97)
In the absence of CF NBS, some infants with border-
line diagnostic-test results may present later with an
atypical CF diagnosis. Individuals with atypical CF tend
to present with milder disease at an older age, with
lower sweat Cl levels, pancreatic sufficiency, and mild
class IV or V mutations. These individuals also probably
survive longer. However, the natural history of atypical
CF is not well defined, and the early identification of
such individuals by NBS may provide much information
about the condition over time. Clinical follow-up proto-
cols are not well established for these individuals, and
the potential positive impact of CF NBS on atypical CF
has not been established. Nevertheless, these infants,
once brought to the attention of the CF care community,
should be monitored. The follow-up proposed for such
infants includes (1) a thorough evaluation by a CF phy-
sician, (2) repeat sweat testing, (3) expanded CFTR mu-
tation analysis for all disease-producing mutations (in-
cluding classes IV and V) if the sweat Cl level remains
elevated, and (4) continued follow-up at a minimum of
1 to 2 visits per year to monitor for any disease devel-
opment.67
Negative Sweat-Test Results
A sweat-test result that is within the reference range
(30 mEq/L) may sometimes occur in infants with 2
CFTR mutations that were detected by CF NBS. Because
the combined screening and diagnostic-test results re-
quire sophisticated analysis to interpret, and because the
infant continues to have a high risk of CF, a CF specialist
should meet with the family to develop a plan for eval-
uation and possible treatment, and genetic counseling
should be offered. The NBS program must be notified
immediately of the discordant result to allow an early
opportunity for quality control to ensure the validity of
the screening result. Genetic counseling and testing of
the parents and extended family may be suggested after
acute care issues have been resolved.
Some positive-screened infants with negative sweat-
test results may be identified to have CF only by later
clinical presentations. Clinical follow-up in parallel with
repeated sweat testing and extended mutation analysis is
the appropriate strategy for resolving the diagnosis in
such cases. It may be more cost efficient to perform the
full gene-mutation analysis immediately to establish a
diagnosis for those in this group, because negative re-
sults from a limited analysis would simply prompt a
more extensive screen.
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APPENDIX 1
Example of letter to health care providers for newborns. Note that the letter to providers can be used as a stand-alone announcement of CF NBS. With attachments, this letter can be
sent as a support document to providers receiving out-of-range results.
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APPENDIX 2
Information for parents of an infant with a positive CF NBS result.
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APPENDIX 3
Interpretation of CF NBS results to be given to the PCP of screened infants in response to clinical concern.
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